The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression

by Lisa Rohrbacher, Lisa Rohrbacher, Bettina Brauchle, Bettina Brauchle, Ana Ogrinc Wagner, Ana Ogrinc Wagner, Michael von Bergwelt-Baildon, Michael von Bergwelt-Baildon, Michael von Bergwelt-Baildon, Veit L. Bücklein, Veit L. Bücklein, Marion Subklewe, Marion Subklewe, Marion Subklewe
Published 2021-03-01